指南与共识造血干细胞移植与细胞治疗白血病

儿童癌症及造血干细胞移植受者系统性抗真菌预防临床实践指南

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
指南 / 共识 · J Clin Oncol · 2020-05-27

该指南由国际多学科专家组制定,系统评价了儿童和成人癌症及HSCT受者的系统性抗真菌预防,共纳入68项随机试验(其中6项仅儿童)。推荐对急性髓系白血病治疗中、异基因HSCT植入前及因GVHD接受系统性免疫抑制的儿童和青少年给予系统性抗真菌预防,并推荐使用棘白菌素或具抗霉菌活性的唑类。

要点

  • 强烈推荐对急性髓系白血病治疗中、异基因HSCT植入前及GVHD系统性免疫抑制的儿童和青少年进行系统性抗真菌预防。
  • 当需要系统性抗真菌预防时,强烈推荐使用棘白菌素或具抗霉菌活性的唑类。
  • 强烈推荐反对常规使用两性霉素作为系统性抗真菌预防。

核心结论

  • 制定了儿童癌症及HSCT受者系统性抗真菌预防的临床实践指南,未来需实施和评估指南符合率及影响。

研究设计与样本

  • 国际多学科专家组(含患者权益代表)制定,采用GRADE方法给出强或弱推荐并将证据等级分为高、中、低或极低。
  • 系统评价纳入68项随机试验,其中6项(9%)仅在儿童人群中开展。

主要发现

  • 系统评价共纳入68项随机试验,其中仅6项(9%)为纯儿童人群研究。

关键数值与推荐

  • 强烈推荐对接受急性髓系白血病治疗的儿童和青少年给予系统性抗真菌预防。
  • 强烈推荐对接受异基因HSCT植入前的儿童和青少年给予系统性抗真菌预防。
  • 强烈推荐对因移植物抗宿主病治疗接受系统性免疫抑制的儿童和青少年给予系统性抗真菌预防。
  • 当需要系统性抗真菌预防时,强烈推荐使用棘白菌素或具抗霉菌活性的唑类。
  • 对于13岁以下儿童,建议(弱推荐)使用棘白菌素、伏立康唑或伊曲康唑;泊沙康唑也可用于13岁及以上者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 系统评价纳入的68项随机试验中仅6项(9%)为纯儿童人群研究,数据对儿科患者的直接性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. METHODS: Recommendations were developed by an international multidisciplinary panel that included a patient advocate. We conducted a systematic review of systemic antifungal prophylaxis in children and adults with cancer and HSCT recipients. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to make strong or weak recommendations and to classify level of evidence as high, moderate, low, or very low. The panel considered directness of the data to pediatric patients. RESULTS: There were 68 randomized trials included in the systematic review, of which 6 (9%) were conducted in a solely pediatric population. Strong recommendations were made to administer systemic antifungal prophylaxis to children and adolescents receiving treatment of acute myeloid leukemia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic immunosuppression for graft-versus-host disease treatment. A strong recommendation was made to administer a mold-active agent with an echinocandin or a mold-active azole when systemic antifungal prophylaxis is warranted. For children younger than 13 years of age, an echinocandin, voriconazole, or itraconazole is suggested. Posaconazole may also be used in those age 13 years or older. A strong recommendation against routine administration of amphotericin as systemic antifungal prophylaxis was made. CONCLUSION: We developed a clinical practice guideline for systemic antifungal prophylaxis administration in pediatric patients with cancer and HSCT recipients. Implementation and assessment of guideline-concordant rates and impacts are important future steps.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol. 2020. PMID: 32459599. doi:10.1200/JCO.20.00158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。